Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 8Myeloid 2Dermatologic 1

Conditions

Melanoma 1103Carcinoma, Non-Small-Cell Lung 281Neoplasms 199Keratosis, Actinic 181Carcinoma, Renal Cell 162Skin Neoplasms 143Colorectal Neoplasms 142Neoplasm Metastasis 140Squamous Cell Carcinoma of Head and Neck 134Breast Neoplasms 118Ovarian Neoplasms 114Carcinoma, Basal Cell 97Stomach Neoplasms 94Pancreatic Neoplasms 93Lung Neoplasms 91Head and Neck Neoplasms 90Lymphoma, T-Cell, Cutaneous 88Uterine Cervical Neoplasms 75Triple Negative Breast Neoplasms 74Sarcoma 68Carcinoma, Hepatocellular 67Prostatic Neoplasms 65Uveal Melanoma 64Carcinoma, Merkel Cell 64Urinary Bladder Neoplasms 63Esophageal Neoplasms 61Carcinoma, Transitional Cell 57Lymphoma 55Endometrial Neoplasms 55Small Cell Lung Carcinoma 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pruritus × Dermatologic × Clear all
NCT02811783 2022-10-28

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Elorac, Inc.

Phase 3 Terminated
59 enrolled
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡